Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Shares Bought by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd grew its holdings in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 742.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 96,367 shares of the company’s stock after purchasing an additional 84,926 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Centessa Pharmaceuticals were worth $3,828,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in CNTA. Millennium Management LLC grew its position in shares of Centessa Pharmaceuticals by 52.9% in the first quarter. Millennium Management LLC now owns 609,188 shares of the company’s stock valued at $8,760,000 after purchasing an additional 210,737 shares in the last quarter. Jane Street Group LLC acquired a new position in Centessa Pharmaceuticals during the first quarter worth $2,176,000. Geode Capital Management LLC boosted its stake in Centessa Pharmaceuticals by 44.7% during the second quarter. Geode Capital Management LLC now owns 87,435 shares of the company’s stock worth $1,149,000 after buying an additional 26,994 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Centessa Pharmaceuticals by 155.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 428,434 shares of the company’s stock valued at $5,630,000 after buying an additional 260,702 shares in the last quarter. Finally, Legal & General Group Plc grew its holdings in Centessa Pharmaceuticals by 29.2% in the 2nd quarter. Legal & General Group Plc now owns 98,256 shares of the company’s stock valued at $1,291,000 after buying an additional 22,205 shares in the last quarter. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Price Performance

CNTA remained flat at $40.50 on Tuesday. The business’s 50 day moving average price is $39.87 and its 200 day moving average price is $32.22. Centessa Pharmaceuticals PLC Sponsored ADR has a 1 year low of $12.74 and a 1 year high of $40.56. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.23. The company has a market cap of $6.27 billion, a price-to-earnings ratio of -22.63 and a beta of 1.11.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.14). As a group, equities analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on CNTA. Lifesci Capital lowered Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 1st. B. Riley Financial cut shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Truist Financial downgraded shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 target price on the stock. in a research note on Monday, April 13th. Leerink Partners lowered shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and boosted their target price for the company from $36.00 to $40.00 in a report on Wednesday, April 1st. Finally, Stephens cut shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Four research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Centessa Pharmaceuticals has a consensus rating of “Hold” and an average price target of $41.33.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical?stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision?making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.